Exact Mass: 459.1089

Exact Mass Matches: 459.1089

Found 14 metabolites which its exact mass value is equals to given mass value 459.1089, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Analogue A

5-Chloro-N-[3-(2-chlorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboximidate

C23H23Cl2N3O3 (459.1116)


   

Mivebresib

N-[4-(2,4-difluorophenoxy)-3-{6-methyl-7-oxo-1H,6H,7H-pyrrolo[2,3-c]pyridin-4-yl}phenyl]ethane-1-sulfonamide

C22H19F2N3O4S (459.1064)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor

   

(2E,5E)-3-benzyl-2-(4-methoxy phenylimino)-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)thiazolidin-4-one

(2E,5E)-3-benzyl-2-(4-methoxy phenylimino)-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)thiazolidin-4-one

C25H21N3O2S2 (459.1075)


   

Flurazepam hydrochloride

Flurazepam dihydrochloride

C21H25Cl3FN3O (459.1047)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018757 - GABA Modulators C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent

   

Aluminum triquinolin-8-olate

Aluminum triquinolin-8-olate

C27H18AlN3O3 (459.1164)


   

4-methyl-N-[2-[(5-oxo-2,3-dihydrothiazolo[2,3-b]quinazolin-3-yl)methylthio]phenyl]benzamide

4-methyl-N-[2-[(5-oxo-2,3-dihydrothiazolo[2,3-b]quinazolin-3-yl)methylthio]phenyl]benzamide

C25H21N3O2S2 (459.1075)


   

Mivebresib

Mivebresib

C22H19F2N3O4S (459.1064)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor

   

Aspartyl-phosphonate-adenosine

Aspartyl-phosphonate-adenosine

C15H20N6O9P- (459.1029)


   

5-chloro-N-[3-(2-chlorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboxamide

5-chloro-N-[3-(2-chlorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboxamide

C23H23Cl2N3O3 (459.1116)


   

4-[(2-Methoxyphenyl)-methylsulfamoyl]benzoic acid [2-[(5-methyl-3-isoxazolyl)amino]-2-oxoethyl] ester

4-[(2-Methoxyphenyl)-methylsulfamoyl]benzoic acid [2-[(5-methyl-3-isoxazolyl)amino]-2-oxoethyl] ester

C21H21N3O7S (459.11)


   

KG5

KG5

C20H16F3N7OS (459.1089)


KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities[1].

   

(4r,5s,6r)-4,5-dihydroxy-6-[(s)-[(3s,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)-3-methoxyoxolan-2-yl](c-hydroxycarbonimidoyl)methoxy]-5,6-dihydro-4h-pyran-2-carboxylic acid

(4r,5s,6r)-4,5-dihydroxy-6-[(s)-[(3s,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)-3-methoxyoxolan-2-yl](c-hydroxycarbonimidoyl)methoxy]-5,6-dihydro-4h-pyran-2-carboxylic acid

C17H21N3O12 (459.1125)


   

(4s,5s,6s)-4,5-dihydroxy-6-[(r)-[(2s,3s,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)-3-methoxyoxolan-2-yl](c-hydroxycarbonimidoyl)methoxy]-5,6-dihydro-4h-pyran-2-carboxylic acid

(4s,5s,6s)-4,5-dihydroxy-6-[(r)-[(2s,3s,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)-3-methoxyoxolan-2-yl](c-hydroxycarbonimidoyl)methoxy]-5,6-dihydro-4h-pyran-2-carboxylic acid

C17H21N3O12 (459.1125)


   

(2r,3s,5s,6s)-6-{[(3s,3ar)-7-chloro-5-(cyanomethyl)-3-hydroxy-3h-cyclopenta[a]inden-3a-yl]oxy}-5-hydroxy-2,3-dimethyl-4-oxooxan-3-yl acetate

(2r,3s,5s,6s)-6-{[(3s,3ar)-7-chloro-5-(cyanomethyl)-3-hydroxy-3h-cyclopenta[a]inden-3a-yl]oxy}-5-hydroxy-2,3-dimethyl-4-oxooxan-3-yl acetate

C23H22ClNO7 (459.1085)